{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:51:46Z","timestamp":1776725506032,"version":"3.51.2"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.diabet.2013.05.005","type":"journal-article","created":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T22:31:22Z","timestamp":1371508282000},"page":"322-329","source":"Crossref","is-referenced-by-count":14,"title":["What is the phenotype of patients with gastrointestinal intolerance to metformin?"],"prefix":"10.1016","volume":"39","author":[{"given":"M.P.","family":"Hermans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.F.","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2013.05.005_bib0005","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJM199508313330902","article-title":"Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group","volume":"333","author":"DeFronzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2013.05.005_bib0010","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9343(97)00254-4","article-title":"Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial","volume":"103","author":"Garber","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.diabet.2013.05.005_bib0015","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2337\/db07-0381","article-title":"Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP","volume":"57","author":"Kim","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2013.05.005_bib0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00125-008-1157-y","article-title":"Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy","volume":"52","author":"Nathan","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2013.05.005_bib0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1463-1326.2010.01349.x","article-title":"Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials","volume":"13","author":"Lamanna","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2013.05.005_bib0030","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","article-title":"Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"55","author":"Inzucchi","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2013.05.005_bib0035","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1185\/03007995.2012.735646","article-title":"Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study","volume":"28","author":"Hermans","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabet.2013.05.005_bib0040","doi-asserted-by":"crossref","first-page":"e1001204","DOI":"10.1371\/journal.pmed.1001204","article-title":"Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials","volume":"9","author":"Boussageon","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.diabet.2013.05.005_bib0045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/CS20110386","article-title":"Cellular and molecular mechanisms of metform: an overview","volume":"122","author":"Viollet","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.diabet.2013.05.005_bib0050","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1046\/j.1365-2036.1998.00399.x","article-title":"Development of a digestive health status instrument: tests of scaling assumptions, structure and reliability in a primary care population","volume":"12","author":"Shaw","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.diabet.2013.05.005_bib0055","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/(SICI)1096-9136(199808)15:8<651::AID-DIA628>3.0.CO;2-A","article-title":"Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus","volume":"15","author":"Scarpello","year":"1998","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabet.2013.05.005_bib0060","series-title":"Recent advances in the pathogenesis, prevention and management of type 2 diabetes and its complications","first-page":"45","article-title":"Residual vascular risk in T2DM: the next frontier","author":"Hermans","year":"2011"},{"key":"10.1016\/j.diabet.2013.05.005_bib0065","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jdiacomp.2012.03.014","article-title":"The multi-faceted outcomes of conjunct diabetes and cardiovascular familial history in type 2 diabetes","volume":"26","author":"Hermans","year":"2012","journal-title":"J Diab Complic"},{"key":"10.1016\/j.diabet.2013.05.005_bib0070","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2013.05.005_bib0075","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s001250051215","article-title":"Comparison of insulin sensitivity tests across a range of glucose tolerance form normal to diabetes","volume":"42","author":"Hermans","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2013.05.005_bib0080","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.diabet.2009.06.003","article-title":"Erectile dysfunction, microangiopathy and UKPDS risk in type 2 diabetes","volume":"35","author":"Hermans","year":"2009","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2013.05.005_bib0085","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2362.2011.02638.x","article-title":"eNOS [Glu298Asp] polymorphism, erectile function and ocular pressure in type 2 diabetes","volume":"42","author":"Hermans","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.diabet.2013.05.005_bib0090","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2013.05.005_bib0095","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jacc.2011.09.073","article-title":"Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy","volume":"59","author":"Gerber","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2013.05.005_bib0100","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/01.STR.0000020091.07144.C7","article-title":"UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK prospective diabetes study risk engine","volume":"33","author":"Kothari","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.diabet.2013.05.005_bib0105","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1475-2840-9-88","article-title":"Log(TG)\/HDL-C is related to both residual cardiometabolic risk and \u03b2-cell function loss in type 2 diabetes males","volume":"9","author":"Hermans","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2013.05.005_bib0110","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1476-511X-11-132","article-title":"The atherogenic dyslipidemia ratio [log(TG)\/HDL-C] is associated with residual vascular risk, \u03b2-cell function loss and microangiopathy in type 2 diabetes females","volume":"11","author":"Hermans","year":"2012","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.diabet.2013.05.005_bib0115","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1742-1241.2004.00291.x","article-title":"Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide","volume":"58","author":"Belcher","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.diabet.2013.05.005_bib0120","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2337\/diacare.27.7.1647","article-title":"PROActive Study Group: the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive)","volume":"27","author":"Charbonnel","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2013.05.005_bib0125","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s00125-006-0176-9","article-title":"Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin","volume":"49","author":"Evans","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2013.05.005_bib0130","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.2337\/dc08-0167","article-title":"Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies","volume":"31","author":"Rao","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2013.05.005_bib0135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1475-2840-8-38","article-title":"A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease","volume":"8","author":"Fisman","year":"2009","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2013.05.005_bib0140","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/eurheartj\/ehr077","article-title":"Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study","volume":"32","author":"Schramm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2013.05.005_bib0145","doi-asserted-by":"crossref","first-page":"e47183","DOI":"10.1371\/journal.pone.0047183","article-title":"White blood cell count and the risk for coronary artery disease in young adults","volume":"7","author":"Twig","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.diabet.2013.05.005_bib0150","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1309\/LM0XULJ3JAYARH9K","article-title":"ABO blood group and coronary artery diseases in Iranian patients awaiting coronary artery bypass graft surgery: a review of 10,641 cases","volume":"40","author":"Anvari","year":"2009","journal-title":"Lab Medicine"},{"key":"10.1016\/j.diabet.2013.05.005_bib0155","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.atherosclerosis.2010.03.012","article-title":"ABO blood group alleles: a risk factor for coronary artery disease. An angiographic study","volume":"211","author":"Carpeggiani","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabet.2013.05.005_bib0160","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(10)61996-4","article-title":"Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies","volume":"377","author":"Reilly","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2013.05.005_bib0165","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1161\/ATVBAHA.112.248757","article-title":"ABO blood group and risk of coronary heart disease in two prospective cohort studies","volume":"32","author":"He","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabet.2013.05.005_bib0170","first-page":"641917","article-title":"ABO blood groups and cardiovascular diseases","author":"Zhang","year":"2012","journal-title":"Int J Vasc Med"},{"key":"10.1016\/j.diabet.2013.05.005_bib0175","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2180-12-94","article-title":"Association between the ABO blood group and the human intestinal microbiota composition","volume":"12","author":"M\u00e4kivuokko","year":"2012","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.diabet.2013.05.005_bib0180","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.diabet.2010.11.002","article-title":"Metformin and digestive disorders","volume":"37","author":"Bouchoucha","year":"2011","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2013.05.005_bib0185","doi-asserted-by":"crossref","first-page":"c2181","DOI":"10.1136\/bmj.c2181","article-title":"Long-term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial","volume":"340","author":"de Jager","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2013.05.005_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cccn.2005.02.001","article-title":"Ferritin in atherosclerosis","volume":"357","author":"You","year":"2005","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.diabet.2013.05.005_bib0195","doi-asserted-by":"crossref","first-page":"e3547","DOI":"10.1371\/journal.pone.0003547","article-title":"Hyperferritinemia is associated with insulin resistance and fatty liver in patients without iron overload","volume":"3","author":"Brudevold","year":"2008","journal-title":"PloS One"},{"key":"10.1016\/j.diabet.2013.05.005_bib0200","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1464-5491.2010.02979.x","article-title":"Do high ferritin levels confer lower cardiovascular risk in type 2 diabetes males?","volume":"27","author":"Hermans","year":"2010","journal-title":"Diabetic Med"},{"key":"10.1016\/j.diabet.2013.05.005_bib0205","article-title":"Involvement of ferritin heavy chain in the preventive effect of metformin against doxorubicin-induced cardiotoxicity","author":"Asensio-L\u00f3pez","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.diabet.2013.05.005_bib0210","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1464-5491.2009.02826.x","article-title":"Handedness, insulin sensitivity and \u03b2-cell function in type 2 diabetes","volume":"26","author":"Hermans","year":"2009","journal-title":"Diabetic Med"},{"key":"10.1016\/j.diabet.2013.05.005_bib0215","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000324680","article-title":"Association between left-handedness and gastrointestinal symptoms","volume":"84","author":"Fujiwara","year":"2011","journal-title":"Digestion"},{"key":"10.1016\/j.diabet.2013.05.005_bib0220","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/FPC.0b013e3283561666","article-title":"Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients","volume":"22","author":"Tarasova","year":"2012","journal-title":"Pharmacogenet Genomics"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363613000955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363613000955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T06:22:48Z","timestamp":1539584568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363613000955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1262363613000955"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2013.05.005","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}